THE CELL HOLDS THE ANSWERS,

AND OUR TESTS UNLOCK THOSE ANSWERS TO EXTEND LIVES.

AR-V7 TEST

The AR-V7 test is the first and only CTC-based liquid-biopsy test that is Medicare reimbursed and clinically-validated for men with metastatic castration-resistant prostate cancer (mCRPC). Requiring only a simple, non-invasive blood draw, this groundbreaking test empowers patients, with their doctors, the confidence to choose the most effective precision therapies.

BIOPHARMA SOLUTIONS

For pharmaceutical and clinical investigation partners, our program delivers a bias-free approach for cancer research, to develop clinical solutions that enhance drug development and provide valuable insights into the dynamics of cancer growth and evolution.

0
CANCER TYPES
0
ACADEMIC PARTNERS
0
PHARMACEUTICAL PARTNERS
0
PUBLICATIONS
>
0
CLINICAL TRIALS
>
0
SINGLE CTC GENOMES SEQUENCED
>
0
PATIENT SAMPLES CONTRACTED

WHAT SOURCES ARE SAYING

Latest Tweets